Home > Research > Publications & Outputs > Prolonged Drug-Releasing Fibers Attenuate Alzhe...

Links

Text available via DOI:

View graph of relations

Prolonged Drug-Releasing Fibers Attenuate Alzheimer's Disease-like Pathogenesis

Research output: Contribution to journalJournal article

Published

Standard

Prolonged Drug-Releasing Fibers Attenuate Alzheimer's Disease-like Pathogenesis. / Salles, Geisa Nogueira; Calió, M.L.; Afewerki, S.; Pacheco-Soares, C.; Porcionatto, M.; Hölscher, Christian; Lobo, Anderson O.

In: ACS Applied Materials and Interfaces, Vol. 10, No. 43, 31.10.2018, p. 36693-36702.

Research output: Contribution to journalJournal article

Harvard

Salles, GN, Calió, ML, Afewerki, S, Pacheco-Soares, C, Porcionatto, M, Hölscher, C & Lobo, AO 2018, 'Prolonged Drug-Releasing Fibers Attenuate Alzheimer's Disease-like Pathogenesis', ACS Applied Materials and Interfaces, vol. 10, no. 43, pp. 36693-36702. https://doi.org/10.1021/acsami.8b12649

APA

Salles, G. N., Calió, M. L., Afewerki, S., Pacheco-Soares, C., Porcionatto, M., Hölscher, C., & Lobo, A. O. (2018). Prolonged Drug-Releasing Fibers Attenuate Alzheimer's Disease-like Pathogenesis. ACS Applied Materials and Interfaces, 10(43), 36693-36702. https://doi.org/10.1021/acsami.8b12649

Vancouver

Salles GN, Calió ML, Afewerki S, Pacheco-Soares C, Porcionatto M, Hölscher C et al. Prolonged Drug-Releasing Fibers Attenuate Alzheimer's Disease-like Pathogenesis. ACS Applied Materials and Interfaces. 2018 Oct 31;10(43):36693-36702. https://doi.org/10.1021/acsami.8b12649

Author

Salles, Geisa Nogueira ; Calió, M.L. ; Afewerki, S. ; Pacheco-Soares, C. ; Porcionatto, M. ; Hölscher, Christian ; Lobo, Anderson O. / Prolonged Drug-Releasing Fibers Attenuate Alzheimer's Disease-like Pathogenesis. In: ACS Applied Materials and Interfaces. 2018 ; Vol. 10, No. 43. pp. 36693-36702.

Bibtex

@article{dcb165ea69724defaa41201d59684483,
title = "Prolonged Drug-Releasing Fibers Attenuate Alzheimer's Disease-like Pathogenesis",
abstract = "Delivering drugs and agents to the brain is a huge challenge, especially for chronic neurodegenerative disorders, such as Alzheimer's disease (AD). For this, prolonged and sustained release methods to increase brain uptake represent an impacting concept. The bioresorbable polymer poly-lactic acid (PLA) has high potential for medical implants; at the same time, glucagon-like peptide-1 (GLP-1) analogues have considerable neuroprotective attributes and represent a therapeutic strategy for AD. Here, a biodevice is produced by electrospinning PLA with a GLP-1 analogue (liraglutide, LG), coated with a thin layer of gelatin. The biodevice is subcutaneously implanted in a transgenic mouse model of AD and LG is released for 14 days in mice serum. After 4 weeks of implantation, crucial hallmarks of the AD are highly diminished: hippocampal senile amyloid β plaque load and neuroinflammatory markers. Furthermore, neurogenesis is enhanced in the subventricular zone, an important neurogenic niche in the brain. The designed biodevice holds great promise for being an affordable candidate to act as a prolonged drug provider, promoting LG mission through increasing its lifetime, constituting a relevant approach for old and impaired brain. {\circledC} 2018 American Chemical Society.",
keywords = "Alzheimer's disease, biodevice, liraglutide, poly-lactic acid fibers, prolonged release, Controlled drug delivery, Functional polymers, Lactic acid, Mammals, Polymeric implants, Targeted drug delivery, Biodevice, Liraglutide, Poly lactic acid fibers, Prolonged release, Neurodegenerative diseases",
author = "Salles, {Geisa Nogueira} and M.L. Cali{\'o} and S. Afewerki and C. Pacheco-Soares and M. Porcionatto and Christian H{\"o}lscher and Lobo, {Anderson O.}",
year = "2018",
month = "10",
day = "31",
doi = "10.1021/acsami.8b12649",
language = "English",
volume = "10",
pages = "36693--36702",
journal = "ACS Applied Materials and Interfaces",
issn = "1944-8244",
publisher = "American Chemical Society",
number = "43",

}

RIS

TY - JOUR

T1 - Prolonged Drug-Releasing Fibers Attenuate Alzheimer's Disease-like Pathogenesis

AU - Salles, Geisa Nogueira

AU - Calió, M.L.

AU - Afewerki, S.

AU - Pacheco-Soares, C.

AU - Porcionatto, M.

AU - Hölscher, Christian

AU - Lobo, Anderson O.

PY - 2018/10/31

Y1 - 2018/10/31

N2 - Delivering drugs and agents to the brain is a huge challenge, especially for chronic neurodegenerative disorders, such as Alzheimer's disease (AD). For this, prolonged and sustained release methods to increase brain uptake represent an impacting concept. The bioresorbable polymer poly-lactic acid (PLA) has high potential for medical implants; at the same time, glucagon-like peptide-1 (GLP-1) analogues have considerable neuroprotective attributes and represent a therapeutic strategy for AD. Here, a biodevice is produced by electrospinning PLA with a GLP-1 analogue (liraglutide, LG), coated with a thin layer of gelatin. The biodevice is subcutaneously implanted in a transgenic mouse model of AD and LG is released for 14 days in mice serum. After 4 weeks of implantation, crucial hallmarks of the AD are highly diminished: hippocampal senile amyloid β plaque load and neuroinflammatory markers. Furthermore, neurogenesis is enhanced in the subventricular zone, an important neurogenic niche in the brain. The designed biodevice holds great promise for being an affordable candidate to act as a prolonged drug provider, promoting LG mission through increasing its lifetime, constituting a relevant approach for old and impaired brain. © 2018 American Chemical Society.

AB - Delivering drugs and agents to the brain is a huge challenge, especially for chronic neurodegenerative disorders, such as Alzheimer's disease (AD). For this, prolonged and sustained release methods to increase brain uptake represent an impacting concept. The bioresorbable polymer poly-lactic acid (PLA) has high potential for medical implants; at the same time, glucagon-like peptide-1 (GLP-1) analogues have considerable neuroprotective attributes and represent a therapeutic strategy for AD. Here, a biodevice is produced by electrospinning PLA with a GLP-1 analogue (liraglutide, LG), coated with a thin layer of gelatin. The biodevice is subcutaneously implanted in a transgenic mouse model of AD and LG is released for 14 days in mice serum. After 4 weeks of implantation, crucial hallmarks of the AD are highly diminished: hippocampal senile amyloid β plaque load and neuroinflammatory markers. Furthermore, neurogenesis is enhanced in the subventricular zone, an important neurogenic niche in the brain. The designed biodevice holds great promise for being an affordable candidate to act as a prolonged drug provider, promoting LG mission through increasing its lifetime, constituting a relevant approach for old and impaired brain. © 2018 American Chemical Society.

KW - Alzheimer's disease

KW - biodevice

KW - liraglutide

KW - poly-lactic acid fibers

KW - prolonged release

KW - Controlled drug delivery

KW - Functional polymers

KW - Lactic acid

KW - Mammals

KW - Polymeric implants

KW - Targeted drug delivery

KW - Biodevice

KW - Liraglutide

KW - Poly lactic acid fibers

KW - Prolonged release

KW - Neurodegenerative diseases

U2 - 10.1021/acsami.8b12649

DO - 10.1021/acsami.8b12649

M3 - Journal article

VL - 10

SP - 36693

EP - 36702

JO - ACS Applied Materials and Interfaces

JF - ACS Applied Materials and Interfaces

SN - 1944-8244

IS - 43

ER -